Companies › MBX Biosciences
3 active drug programs in 3 registered trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Canvuparatide PTH analog (parathyroid hormone analog) | PTHR1 | Phase 3 | Hypoparathyroidism | Jan 2028 |
| MBX 2109 PTH receptor agonist (presumed) | – | Phase 2 | Hypoparathyroidism | May 2028 |
| MBX 4291 | – | Phase 1 | Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07142707 | MBX 4291 | Phase 1 | Obesity | Metabolic and endocrine | Oct 2026 |
| NCT07699471 | Canvuparatide | Phase 3 | Hypoparathyroidism | Metabolic and endocrine | Jan 2028 |
| NCT06531941 | MBX 2109 | Phase 2 | Hypoparathyroidism | Metabolic and endocrine | May 2028 |
Cash and short-term investments of $482m on 2026-09-30; operating cash outflow about $104m a year; runway about 55 months at that burn, to May 2031; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Amylyx Pharmaceuticals Rhythm Pharmaceuticals Vogenx Calcilytix Therapeutics, Inc., a BridgeBio company vTv Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.